Dishman Pharmaceuticals & Chemicals Ltd will acquire the fine chemicals, vitamin D and vitamin D analogues business of Solvay Pharmaceuticals for an undisclosed amount.
As part of this deal, all facilities, people and activities at Solvay's Veenendaal site in the Netherlands and technology, patent and intellectual property rights for fine chemicals, vitamin D and vitamin D analogues business will be transferred to the company, Dishman informed the BSE.
The intended sale of Solvay's site in Veenendaal is a result of Solvay Pharmaceuticals strategy to focus on the main therapeutic areas of cardiometabolic and neuroscience treatments and hive off the non-core business.
Dishman's manufacturing plants and research facilities are spread across two locations in Gujarat. The company has an approved US FDA facility and cGMP compliant manufacturing facilities. In 2006, the company acquired Carbogen Amcis, a Switzerland based contract research and manufacturing facility, which is fully integrated.
(Source: Economic Times)
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment